Clinical Trials

ABCD

The aim of this study is to investigate the influence of rituximab (Rixathon®) on the progression of disease in patients with amyotrophic lateral sclerosis (ALS) compared to a placebo. The study is funded by the German Federal Ministry of Education and Research (BMBF).

CELIA (A trial for the treatment of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia with BIIB80))

The CELIA study investigates a therapeutic option for Alzheimer's disease by focusing on a protein called tau. It is examining whether different doses of the study drug BIIB080 have potential side effects and can influence the progression of Alzheimer's disease.

DIAN-TU-001 (A Phase II/III Randomized, Double‐Blind, Placebo‐Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease)

Participation addresses persons with a dominant hereditary Alzheimer's disease. The aim of the study is to assess the safety, tolerability and efficacy of a drug treatment targeting both amyloid and tau pathology.

ENABLE (Patient- and care-related benefits of amyloid PET imaging)

The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.

EPI589-15-002(Phase 2A safety and biomarker study of the drug substance EPI-589 in patients with mitochondrial subtype of Parkinson's disease)

>>> Study already completed! <<< The primary objective of the study is to assess the safety of EPI-589 when applied to patients with idiopathic and genetic Parkinson's disease (e. g. hematology, electrocardiogram).

GENERATION HD1 (Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease)

>>> Study already completed <<< The GENERATION HD1 study will evaluate the efficacy and safety of treatment with RG6042 administered once every two months (every eight weeks) or once every four months (every 16 weeks) over a 25-month period. This modified global study will enroll up to 660 patients with manifest Huntington's disease (HD) at 80-90 centers worldwide.

GENERATION HD2 (Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen (R) in Individuals with Prodomal and Early Manifets Huntigton's Disease)

This study will enroll up to 360 people with early manifest Huntington's disease or carriers of the abnormal huntingtin gene with very early, subtle symptoms of HD. The GENERATION HD2 study will evaluate the safety, biomarkers and efficacy of the investigational drug tominersen, which will be administered over a period of 16 months.

IONIS-MAPTRX-CS1 (A placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered ISIS 814907 in patients with mild Alzheimer’s disease)

>>> Study already completed! <<< With this study, doctors want to investigate the safety and efficacy of the investigational drug and compare it to a placebo that looks like the investigational drug but contains no active ingredients.

M-Star (placebo-controlled, parallel-group study to evaluate the efficacy and safety of BHV-3241 in subjects with multiple system atrophy)

>>> Study already completed! <<< Our team of physicians is studying a study drug designed to suppress an enzyme called myeloperoxidase (MPO), which is believed to cause inflammation and damage to neurons in the brains of patients with multisystem atrophy.

NIO752 (Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy)

Adult patients suffering from progressive supranuclear gaze palsy (PSP) are eligible for enrollment in this study. Gaze palsy is a form of atypical Parkinson's syndrome.

ORCHESTRA (Clinical research study to evaluate the use of an investigational medication called UCB0599 in men and women with early-stage Parkinson’s disease)

This study investigates the safety, tolerability, and pharmacokinetics of orally administered UCB0599 in study participants with early-stage Parkinson's disease.

PASADENA - A Placebo-controlled study to evaluate the efficacy of intravenous RO7046015 (PRX002) in patients with early Parkinson’s disease

TAK-341-2001 (A Study of TAK-341 in Treatment of Multiple System Atrophy)

This study helps answer important medical questions about an investigational drug called TAK-341, such as: How effective is it in treating people who have MSA? What side effects may occur?

VO659-CT01 (A study on Vo659 in the treatment of Spinocerebellar Ataxia Type 1, 3 and Huntington's disease)

This clinical trial is open to patients with SCA1, SCA3 and Huntington's disease, a group of rare, congenital genetic disorders that affect specific areas of the brain. The disorders can cause disturbances in balance, coordination, walking, swallowing and speech, as well as mental and psychological problems.

Vorinostat_AD (A dose-finding study to address safety (and efficacy) of Vorinostat in Alzheimer‘s Disease)

The objective of this clinical trial is to determine a tolerable and tolerable dose of the drug vorinostat in elderly patients with mild Alzheimer's disease.